Nanjing Leads tests investor appetite for Lag3
But BeOne canned its alcestobart deal in May.
Sino takes out the rest of Merck’s partner
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
But BeOne canned its alcestobart deal in May.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
